TABLE 1.
Overview of included countries with relevant health technology assessment organizations and clinical guidelines.
| Country | HTA organizations | Reference to website for HTA reports | Clinical guidelines | Year | Reference |
|---|---|---|---|---|---|
| France | Haute Autorité de Santé (HAS) | 21 | HAS, Actes et prestations, affection de longue durée, Sclérose en plaques | 2015 | 22 |
| Germany | Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | 23 | DGN/KKNMS Leitlinie zur Diagnose und Therapie der MS | 2014 | 24 |
| Der Gemeinsame Bundesausschuss (G‐BA) | 25 | ||||
| The Netherlands | Dutch National Healthcare Institute (ZIN) | 26 | Nederlandse Vereniging voor Neurologie, Multipele Sclerose | 2012 | 27 |
| Addendum bij de richtlijn Multiple Sclerose | 2020 | 28 | |||
| Poland | Agency for Health Technology Assessment and Tariff System (AOTMiT) | 29 | Leczenie stwardnienia rozsianego Zalecenia Polskiego Towarzystwa Neurologicznego | 2016 | 30 |
| Sweden | Dental and Pharmaceutical Benefits Agency (TLV) | 31 | Nationella riktlinjer Socialstyrelsen, Vård vid multipel skleros och Parkinsons sjukdom | 2016 | 32 |
| Svenska MS‐sällskapet, Läkemedel | 2019–2021 | 33 | |||
| UK | National Institute for Health and Care Excellence (NICE) | 34 | National Health Service (NHS) Treatment Algorithm for Multiple Sclerosis Disease‐Modifying Therapies | 2019 | 35 |
| Association of British Neurologists: revised guidelines for prescribing disease‐modifying treatments in multiple sclerosis | 2015 | 36 | |||
| European | European Network for Health Technology Assessment (EUnetHTA) | 20 | ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis | 2018 | 19 |